Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-cash Items: 2016-2025

Historic Non-cash Items for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $4.1 million.

  • Intellia Therapeutics' Non-cash Items fell 0.12% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 0.12%. This contributed to the annual value of $350,000 for FY2024, which is 99.03% down from last year.
  • Intellia Therapeutics' Non-cash Items amounted to $4.1 million in Q3 2025, which was up 1,504.64% from $255,000 recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Non-cash Items registered a high of $974.5 million during Q2 2021, and its lowest value of $255,000 during Q2 2025.
  • Its 3-year average for Non-cash Items is $20.8 million, with a median of $4.3 million in 2024.
  • As far as peak fluctuations go, Intellia Therapeutics' Non-cash Items soared by 16,607.99% in 2021, and later crashed by 99.35% in 2022.
  • Intellia Therapeutics' Non-cash Items (Quarterly) stood at $493.0 million in 2021, then crashed by 99.35% to $3.2 million in 2022, then skyrocketed by 1,016.73% to $35.9 million in 2023, then plummeted by 88.18% to $4.2 million in 2024, then fell by 0.12% to $4.1 million in 2025.
  • Its Non-cash Items stands at $4.1 million for Q3 2025, versus $255,000 for Q2 2025 and $4.5 million for Q1 2025.